Diabetes Solutions Landscape, US Phase 2, Part 1

Part
01
of four
Part
01

Diabetes Solutions Landscape KPI - Coheso Track3

We were able to uncover a comprehensive amount of data regarding Coheso's Track3 app. A brief summary of all applicable results is provided below. The complete, detailed data has been entered in the appropriate cells in row 16, columns T through AO on the attached spreadsheet.

Summary

Coheso, Inc.'s Track3 application for iOS and Android has not received regulatory approval from FDA, EMA, or CE.
The American Diabetic Association acknowledged Track3 diabetes management in a 2012 clinical review.

•Track3 has formed no private or public partnerships nor is the company reimbursed by any outside partners.

Coheso is a well-established company, launched in 2003 by Ratna Nirkondar. The company was incorporated in 2004. It has a reported net worth of $2.4 million.

The Google Play store reports 1,000 users of Coheso's Track3 application, iOS App Store claims an additional 843 downloads. In the absence of a precise user count, we have made the following assumptions. a.) Google Play Store and iOS App Store control the majority of mobile app sales. b.) When the reported total user counts from both stores are combined, the resulting total will be a reasonable representation of the total mobile app consumers
The application is offered in English only.
Users who have reviewed Track3 on iOS App Store or Google Play Store were generally very satisfied with the application. 85% of the online reviews submitted, ranked the application 4-stars or above. (787 out of 925) The quoted rankings are the sum total of the Google Play Store rank and review results combined with the iOS App Store rank and reviews

Users most often cite the vast amount of information packed into the app, along with its glucose level tracker and carbohydrate counter.

The negative reviews cited an incompatibility with the users existing system which keeps the app from syncing with the user's other devices. There were frequent complaints regarding unresponsive support staff.

The stated goal behind the development of Track3, was the desire to facilitate a better quality of life for diabetic patients by providing a centralized, simplified hub where they could efficiently manage the data vital to maintaining their glucose balance.

The users have awarded the application 5-stars (out of 5) in well over half of the submitted reviews (558 out of 925). This solid user appreciation for the application is a strong argument that Coheso has indeed achieved their stated goal and had an impact on diabetes management and patient care. As referenced above, the rankings were created by combining the total user reviews from iOS and Google . The original ranking is unchanged as each level was combined with the matching level only. (5-star Google combined with 5-star iOS)

Healthcare insiders have weighed in as well, consistently ranking Track3 as one of the best mobile diabetes management apps.

Conclusion

The information above is a brief summary of our findings, the full, detailed data has been entered into the appropriate cells, located in Row 16, Columns T thru AO of the attached spreadsheet.
Part
02
of four
Part
02

Diabetes Solutions Landscape KPI - Sanofi GoMeals

GoMeals is a free app created by Sanofi, a large, multi-national pharmaceuticals company based in France. In just the fourth financial quarter of 2017, Sanofi had a revenue of approximately 2 billion USD. Instead of receiving venture capital funding, Sanofi, in fact, has its own venture capital arm, entitled "Sanofi-Genzyme BioVentures (SGBV)." Sanofi's funding status is listed as "M&A (Mergers and Acquisitions" by CrunchBase.

FURTHER FINDINGS

GoMeals is an app that is meant to "...help you make healthy lifestyle choices at home or on the go. GoMeals includes tools for eating healthy, staying active, and tracking your blood glucose levels." It is marketed towards diabetics and is available only in English. The FDA, nor any other organizations (as could be found), regulate this particular app. Across GooglePlay and iTunes, the GoMeals app had, as of the writing of this brief, 1,907 ratings. On GooglePlay, the app had an average rating of 3.9. On iTunes, the app had an average rating of 2.3.

Because the app is free, there is no need for reimbursement. There is no publicly available information to indicate that GoMeals has a relationship with a public or private payee.

For the full findings and analysis, please consult Row 17, T- A0 in the US tab of the attached spreadsheet.
Part
03
of four
Part
03

Diabetes Solutions Landscape KPI - Roche Accu Chek

Accu-Check is a digital service from Roche Diabetes Care, Inc., which aims to help users track and manage their blood sugar more effectively. All of the relevant data and information about Accu-Check is included in the attached spreadsheet, and is summarized below.

regulatory authorities

Accu-Check was approved by the FDA in 2015, however it has since been recalled five times. The most recent recall was in February, 2018, and was due to a bug which could cause users to administer an incorrect dose of insulin. It has not been recommended by any of the medical bodies mentioned in the spreadsheet.

funding & Costs

Accu-Check is a product of Roche Diabetes Care, Inc., which is an established company that has operated in this space for over forty years. They are operating it themselves, and have not received funding from any other organizations. The app is free, and so there is no need for it to be reimbursed.

user data

While Roche does not release information about its users, according to the most recent FDA recall there are 67,040 current unique users of the most up to date version of the service. These users have only moderate satisfaction with the service. It has received 529 ratings on Google Play which come to an average of three stars, and 92 ratings on the App Store which come to an average of two stars. The app is available in thirty languages - English, Croatian, Czech, Danish, Dutch, Estonian, Finnish, French, German, Greek, Italian, Japanese, Korean, Latvian, Lithuanian, Macedonian, Malay, Norwegian Bokmål, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovenian, Spanish, Swedish, Thai, Traditional Chinese, and Turkish.

goals and impact

Accu-Check aims to help its patients to more accurately measure and manage their blood sugar, however Roche has not publicly released any data on the effectiveness of its product, nor have any independent tests been done. Roche only mentions goals for community impact of their products.

conclusion

Accu-Check is an effort by Roche Diabetes Care to help users with Diabetes better measure their blood sugar. Though it has some problems with the FDA and mixed reviews, it seems to have a reasonably large user base. All of this data is provided in more detail in the attached spreadsheet.

Part
04
of four
Part
04

Diabetes Solutions Landscape KPI - Onduo

Onduo is an innovative attempt to improve diabetes care by using digital technology to integrate monitoring by the patient's care team with immediate advice, as well as coaching with device recommendations and monitoring. Unfortunately, as a small, private company, Onduo does not provide extensive information to the public. Therefore, we were not able to locate specific data for each of the relevant KPIs. In particular, Onduo does not release information about the number of users it has, and if there is any publicly available data about patient outcomes, it has not been released at this time. All the information we have been able to locate has been added to the attached spreadsheet, and is briefly summarized below.

Summary

Onduo meets the inclusion criteria because it is primarily a digital service. The company aims to help users enact behavioral changes to help manage their diabetes, and also to make the best use of their medicine and devices via a digital diabetes clinic. Moreover, it has been backed by Sanofi and Alphabet Inc, with Alphabet Inc also owning Verily Life Sciences. Onduo only partners with products that have been approved by the FDA.

Onduo has a limited social media presence, and is not mentioned on any major review aggregator sites. Onduo has a Facebook page, and the limited number of reviews are favorable. However, it is noted that it is difficult to draw conclusions about user satisfaction based on only 14 ratings. Investors appear enthusiastic about Onduo, with French healthcare giant Sanofi and Google parent company Alphabet Inc. each providing Onduo with a remarkable $250 million in seed capital.

Determining the precise number of users is difficult. Onduo is a private company, and therefore does not release any information about its users to the public. The fact that it provides medical services makes data about its customers doubly unavailable, as there may be applicable healthcare privacy laws limited the public release of data. Moreover, Onduo does not release revenue information, from which user numbers might be estimated. However, a key component of the Onduo services (which is mentioned several times on their website) is the Onduo app. The app has received fewer than 15,000 downloads on iOS, and fewer than 5,000 downloads on Android. While there may be some users who choose not to use the mobile app, based on Onduo's own description of their service, it would seem to be an important part of the service they provide. Therefore, the total number of users is likely not much larger than the total number of app downloads.

Conclusion

Onduo is an innovative service that provides a digital diabetes clinic to help its users manage their condition. It has received funding from major backers, and a small number of positive reviews on social media. However, it appears to have a relatively small user base. All this information is provided in far more detail in the attached spreadsheet.

Sources
Sources